Resources
26 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 10/12/2023 (updated 3/27/2024)
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured fentanyl drug products.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 3/7/2023 (updated 3/27/2024)
Qualify for tax-free educational loan repayment while becoming part of the solution to increase access to health care in your community. Join more than 18,000 National Health Service Corps (NHSC) members providing culturally competent care to medically underserved people across the country.
Posted 1/31/2023 (updated 3/27/2024)
Training Material
Posted 12/21/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration released a notice of proposed rulemaking that would allow certified opioid treatment programs to begin prescribing the drug via audio-only or video-enabled telehealth. See additional information under Policy Updates below. The proposed changes come on top of recent findings by HHS of the positive impact of its revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that removed two longstanding requirements for obtaining a waiver to treat up to 30 patients with buprenorphine: 1) the requirement for specific training, and 2) the need for otherwise eligible clinicians to certify their ability to provide or refer patients for counseling and other services. Rural primary care providers have obtained the DEA waiver at a lower rate than urban clinicians; decreased burden and greater flexibility in the guidelines, along with broader use of telehealth could help close that gap.
Posted 11/22/2022 (updated 3/27/2024)
Over its 36 year history, the Federal Office of Rural Health Policy has provided billions of dollars in funding to increase health care access, strengthen health networks, and focus on care quality improvements for Critical Access Hospitals and small rural hospitals. In fiscal year 2022, the Health Resources and Services Administration (HRSA) – through the Federal Office of Rural Health Policy (FORHP) – provided approximately $408 million in funding to increase health care access, strengthen health networks, and focus on care quality improvements for Critical Access Hospitals and small rural hospitals.
Posted 10/17/2022 (updated 3/27/2024)
HRSA's Health Workforce Connector connects skilled health professionals to communities in need. With this resource, search thousands of employment and training opportunities in underserved communities across the nation, create a personal profile so recruiters can find you to fill open positions and access 24,000 + healthcare facilities located in rural and underserved communities.